Peter N. Mugyenyi

Kampala, C, Uganda

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.

Journal: Journal of the International AIDS Society

Published: June 19, 2021

Translocated microbiome composition determines immunological outcome in treated HIV infection.

Translocated microbiome composition determines immunological outcome in treated HIV infection.

Journal: Cell

Published: May 05, 2020

Effectiveness of a mobile antiretroviral pharmacy and HIV care intervention on the continuum of HIV care in rural Uganda.

Effectiveness of a mobile antiretroviral pharmacy and HIV care intervention on the continuum of HIV care in rural Uganda.

Journal: AIDS care

Published: April 14, 2020

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.

Journal: The Lancet. Digital health

Published: September 19, 2019

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.

Journal: PloS one

Published: July 30, 2019

Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.

Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: July 29, 2019

Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children.

Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children.

Journal: The Journal of antimicrobial chemotherapy

Published: February 11, 2019

Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study.

Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study.

Journal: PloS one

Published: January 25, 2019

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

Journal: The lancet. HIV

Published: October 17, 2018

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 23, 2018

Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.

Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 08, 2018

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

Journal: AIDS research and human retroviruses

Published: January 23, 2018

Showing 1-12 of 62

Last Updated: 09/26/2026